Direct Meds Launches NAD+ Injections via Telehealth for Cellular Repair

Direct Meds now offers NAD+ injections through a telehealth service available in most US states. The treatment, which involves a compounded prescription medication, is designed to support cellular energy and repair. Patients must first consult with a licensed clinician to determine suitability and dosage.

NAD+ is a coenzyme that plays a key role in energy production and DNA repair. Research suggests it may influence cognitive function and overall cellular health. Unlike over-the-counter supplements, NAD+ injections are administered subcutaneously and require medical supervision.

Direct Meds operates as a telehealth platform, connecting patients with clinicians who assess individual needs. Dosage is not chosen by the consumer but determined by the evaluating healthcare provider. The service follows a monthly pricing model, with injections compounded by a 503A/503B-certified pharmacy partner. While generally well-tolerated, NAD+ injections may not be suitable for everyone. Potential side effects are reviewed on a case-by-case basis by the prescribing clinician. The therapy itself is not FDA-approved as a finished product, though the compounding process adheres to regulatory standards. For inquiries, consumers can contact Direct Meds by phone at (888) 696-7176 or via email at [email protected]. The company emphasises that NAD+ peptides sold as 'research chemicals' are not approved for human use and lack the same oversight as prescription treatments.

NAD+ injections from Direct Meds provide an alternative to over-the-counter supplements, with personalised medical evaluation required. The service is available through telehealth in most US states, though the treatment remains unapproved by the FDA as a final product. Patients must consult a licensed clinician before starting therapy.